Skip to main content
Top

19-05-2025 | Myasthenia Gravis | Brief Communication Free for a limited time

Delayed diagnosis of myasthenia gravis caused by concurrent anxiety symptoms

Authors: Valentina Gasparini, Daniele Mattavelli, Leonardo Pantoni

Published in: Neurological Sciences

Login to get access

Abstract

Background

Myasthenia gravis (MG) is the most frequent autoimmune disorder of the neuromuscular junction. Patients with MG often have concomitant psychiatric complications, with high prevalence rate of depression and anxiety. These disturbances may sometimes delay the diagnosis of MG. Moreover, the prescription of drugs used in anxiety disorder, such as benzodiazepines, interferes with the correct function of the neuromuscular junction, and may determine worsening of the symptoms.

Case presentation

In this paper, we report the case of a 54-year-old woman with bulbar onset of MG and without circadian fluctuations who, during the COVID pandemic and partly consequent to it, was initially diagnosed with anxiety disorder, and treated with psychiatric drugs that eventually worsened the picture and led her to the emergency room.

Conclusion

Our case is an example of how a concurrent anxiety disorder may mask and postpone the diagnosis of MG in patients without a clear modification of symptoms during the day. Misdiagnosing MG with anxiety disorder may have severe consequences.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Delayed diagnosis of myasthenia gravis caused by concurrent anxiety symptoms
Authors
Valentina Gasparini
Daniele Mattavelli
Leonardo Pantoni
Publication date
19-05-2025
Publisher
Springer International Publishing
Published in
Neurological Sciences
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-025-08240-5

EAN 2025

Unlock your free and exclusive access to the latest news and expert interviews from the European Academy of Neurology's annual congress.

Read more

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest